To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Deudextromethorphan/quinidine

From Wikipedia, the free encyclopedia

Deudextromethorphan/quinidine
Combination of
DeudextromethorphanSigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor
QuinidineAntiarrhythmic agent, CYP2D6 inhibitor
Clinical data
Other namesAVP-786; CTP-786; d-DM/Q; d6-DM/Q; d-DXM/Q; d6-DXM/Q
Routes of
administration		By mouth

Deudextromethorphan/quinidine (d-DXM/Q; developmental code names AVP-786, CTP-786) is a combination of deudextromethorphan (d-DXM; deuterated (d6) dextromethorphan (DXM)) and quinidine (Q) which is under development by Avanir Pharmaceuticals for the treatment of a variety of neurological and psychiatric indications.[1][2] The pharmacological profile of d-DXM/Q is similar to that of dextromethorphan/quinidine (DXM/Q).[2] DXM and d-DXM act as σ1 receptor agonists, NMDA receptor antagonists, and serotonin–norepinephrine reuptake inhibitors, among other actions, while quinidine is an antiarrhythmic agent acting as a CYP2D6 inhibitor.[2] Quinidine inhibits the metabolism of DXM and d-DXM into dextrorphan (DXO), which has a different pharmacological profile from DXM.[2] Deuteration of DXM hinders its metabolism by CYP2D6 into DXO, thereby allowing for lower doses of quinidine in the combination.[2] This in turn allows for lower potential for drug interactions and cardiac adverse effects caused by quinidine.[2] As of September 2020, d-DXM/Q is in phase 3 clinical trials for agitation, phase 2/3 trials for schizophrenia, and phase 2 trials for brain injuries, impulse control disorders, major depressive disorder, and neurodegenerative disorders.[1]

References

  1. ^ a b "Deudextromethorphan - Avanir Pharmaceuticals - AdisInsight".
  2. ^ a b c d e f Ahmed M, Malik M, Teselink J, Lanctôt KL, Herrmann N (July 2019). "Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia". Drugs Aging. 36 (7): 589–605. doi:10.1007/s40266-019-00668-7. PMID 30957198. S2CID 102348513.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This page was last edited on 25 January 2024, at 19:33
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy